Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Dose, Open-Label, Parallel-Group Pharmacokinetic Study of VCT220 in Subjects With Moderate Renal Impairment and Matched Subjects With Normal Renal Function

NCT07347808 is registered in ClinicalTrials.gov with Vincentage Pharma Co., Ltd as lead sponsor.

NCT NCT07347808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07347808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Dose, Open-Label, Parallel-Group Pharmacokinetic Study of VCT220 in Subjects With Moderate Renal Impairment and Matched Subjects With Normal Renal Function
Lead sponsor
Vincentage Pharma Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
December 25, 2025
Completion date
February 18, 2026
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight